Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03G. D’Addario, Daniel Betticher, Michael Mayer et al.|Annals of Oncology|2007Cited by 43
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)Francesco Zappa, Miklos Pless, C. Droege et al.|Lung Cancer|2012Cited by 32
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)Christoph Rochlitz, Khalil Zaman, Thomas Ruhstaller et al.|Annals of Oncology|2010Cited by 26
9147 Bevacizumab and erlotinib as first-line therapy in advanced (stage IIIB/IV) non-squamous non-small-cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression – a multicenter phase II trial of SAKKFrancesco Zappa, Miklos Pless, C. Droege et al.|European Journal of Cancer Supplements|2009Cited by 3
Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial, SAKK 19/05.Francesco Zappa, Miklos Pless, C. Droege et al.|Journal of Clinical Oncology|2011Cited by 3